Soufflé Therapeutics is a biotechnology company focused on discovering and developing cell-specific ligands to deliver siRNA-based medicines that are rationally designed to cross cell membranes and target specific disease mechanisms with high precision. The company aims to create potent, precise, and safe genetic medicines for a variety of diseases, including metabolic disorders, facioscapulohumeral muscular dystrophy, and cardiomyopathies caused by phospholamban gene mutations.
1
Round
1
Industry
3
Tags
Oct 13, 2026
Latest raise
Funding activity · 1 round
Oct 13, 2026
$135M
Series B
Led by Juvia Group
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
